Client News
Roquefort Therapeutics PLC – Director/PDMR ShareholdingRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Dr Darrin Disley, a Non-Executive Director, has purchased ordinary shares in the Company, as detailed below:
|
Number of Ordinary Shares |
Average Price Paid Per Share |
Total Consideration Paid |
|
269,935 |
7.35 pence |
£19,999.95 |
Following the above purchase of shares, Dr Disley holds an interest in 1,495,901 Company ordinary shares, representing 1.16% of the Company’s issued share capital.
Director/PDMR Shareholding – 07:00:07 02 Aug 2023 – ROQ News article | London Stock Exchange
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.